Better CD4+ T cell recovery in Brazilian HIV-infected individuals under HAART due to commulative carriage of SDF-1-3′A, CCR2-V64I, CCR5-D32 and CCR5-promoter 59029A/G Polymorphisms

Current HIV Research

Volumn 6, Issue 5, 2008, Pages 466-473

  Rigato, Paula O ^a   Hong, Marisa A ^a,b   Casseb, Jorge ^a   Ueda, Mirthes ^c   de Castro, Isac ^a   Bernard, Gil ^a,b   Duarte, Alberto J S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Seção de Sorologia ^*  (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

CCR2 V64I; CCR5 D32; CCR5 promoter 59029A G; Chemokine receptors; HIV 1; Polymorphisms; SDF 1 3 A

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; BRAZIL; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG RESPONSE; ETHNIC DIFFERENCE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; WILD TYPE;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CXCL12; CHEMOKINES; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION, MISSENSE; POINT MUTATION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, CCR2; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE;

EID: 53849101835     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208785861131     Document Type: Review

References (59)

1. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MEP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811-5.
2. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272: 872-7.
3. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73.
4. Deng HK, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997; 388: 296-300.
5. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 1996; 271: 17161-6.
6. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-62.
7. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77.
8. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
9. Alkhatib G, Berger EA. HIV Coreceptors: From Discovery and Designation to New Paradigms and Promise. Eur J Med Res 2007; 12: 375-84.
10. Theodorou I, Capoulade C, Combadiere C, Debre P. Genetic control of HIV disease. Trends Microbiol 2003; 11: 392-7.
11. Samson M, Stordeur P, Labbe O, Soularue P, Vassart G, Parmentier M. Molecular cloning and chromosomal mapping of a novel human gene, ChemR1, expressed in T lymphocytes and polymorphonuclear cells and encoding a putative chemokine receptor. Eur J Immunol 1996; 26: 3021-8.
12. Barroga CF, Raskino C, Fangon MC, et al. The CCR5Delta32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment. J Infect Dis 2000; 182:413-9.
13. Singh KK, Barroga CF, Hughes MD, et al. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. J Infect Dis 2003; 188: 1461-72.
14. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998; 4: 350-3.
15. Martin MP, Dean M, Smith MW, et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282: 1907-11.
16. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998; 352: 866-70.
17. An P, Martin MP, Nelson GW, et al. Influence of CCR5 promoter haplotypes on AIDS progression in African-Americans. AIDS 2000; 14: 2117-22.
18. Knudsen TB, Kristiansen TB, Katzenstein TL, Eugen-Olsen J. Adverse effect of the CCR5 promoter -2459A Allele on HIV-1 disease progression. J Med Virol 2001; 65: 441-4.
19. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science J998; 279: 389-93.
20. Vidal F, Peraire J, Domingo P, et al. Lack of association of SDF-1 3′A variant allele with long-term nonprogressive HIV-1 infection is extended beyond 16 years. J Acquir Immune Defic Syndr 2005; 40: 276-9.
21. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-641, and SDF-1 3′A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001; 135: 782-95.
22. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997; 277: 959-65.
23. Anzala AO, Ball TB, Rostron T, O'Brien SJ, Plummer FA, Rowland-Jones SL. CCR2-641 allele and genotype association with delayed AIDS progression in African women. University of Nairobi Collaboration for HIV Research. Lancet 1998; 351: 1632-3.
24. Michael NL, Louie LG, Rohrbaugh AL, et al. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nat Med 1997; 3: 1160-2.
25. Eugen-Olsen J, Iversen AK, Benfield TL, Koppelhus U, Garred P. Chemokine receptor CCR2b 641 polymorphism and its relation to CD4 T-cell counts and disease progression in a Danish cohort of HIV-infected individuals. Copenhagen AIDS cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 110-6.
26. Vilades C, Broch M, Plana M, et al. Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects. J Acquir Immune Defic Syndr 2007; 44: 132-138.
27. Dolan MJ, Kulkarni H, Camargo JF, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007; 8: 1324-36.
28. Brigido LFM, Rodrigues R, Casseb J, et al. Impact of adherence to antiretroviral therapy in HIV-1-Infected patients at a university public service in Brazil. AIDS Patient Care STDS 2001; 15: 587-93.
29. Michael NL, Louie LG, Sheppard HW. CCR5-delta 32 gene deletion in HIV-1 infected patients. Lancet 1997; 350: 741-2.
30. Hendel H, Henon N, Lebuanec H, et al. Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 381-6.
31. van Rij RP, Broersen S, Goudsmit J, Coutinho RA, Schuitemaker H. The role of a stromal cell-derived factor-1 chemokine gene variant in the clinical course of HIV-1 infection. AIDS 1998; 12: F85-90.
32. Lucotte G. Frequencies of the CC chemokine receptor 5 delta 32 allele in various populations of defined racial background. Biomed Pharmacother 1997; 51: 469-73.
33. Lucotte G, Mercier G. Distribution of the CCR5 Gene-32bp deletion in Europe. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 174-7.
34. Battiloro E, Andreoni M, Parisi SG, et al. Distribution of the CCR5 delta32 allelc in Italian HIV type 1-infected and normal individuals. AIDS Res Hum Retroviruses 2000; 16: 181-2.
35. Lewandowska M, Franciszkiewicz K, Prokop J, Ofori H, Jagodzinski PP. Distribution of two HIV-1-resistant polymorphisms (SDF1-3′A and CCR2-641 alleles) in the Polish population. J Hum Genet 2002; 47: 585-9.
36. Lucotte G. Frequencies of 32 base pair deletion of the (Delta 32) allele of the CCR5 HIV-1 co-receptor gene in caucasians: a comparative analysis. Infect Genet Evol 2002; 1: 201-5.
37. Apostolakis S, Baritaki S, Krambovitis E, Spandidos DA. Distribution of HIV/AIDS protective SDF1, CCR5 and CCR2 gene variants within Cretan population. J Clin Virol 2005; 34: 310-4.
38. Verma R, Gupta RB, Singh K, et al. Distribution of CCR5delta32, CCR2-641 and SDF1-3′A and plasma levels of SDF-1 in HIV-1 seronegative North Indians. J Clin Virol 2007; 38: 198-203.
39. Libert F, Cochaux P, Beckman G, et al. The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. Hum Mol Genet 1998; 7: 399-406.
40. Parra FC, Amado RC, Lambertucci JR, et al. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 2003; 100: 177-82.
41. Pimenta JR, Zuccherato LW, Debes AA, et al. Color and genomic ancestry in Brazilians: a study with forensic microsatellites. Hum Hered 2006, 62: 190-5.
42. Reiche EM, Watanabe MA, Bonametti AM, et al. Stromal cell-derived factor 1 (SDF1) genetic polymorphism in a sample of healthy individuals, seronegative individuals exposed to human immunodeficiency virus type 1 (HfV-1) and patients infected with HIV-1 from the Brazilian population. Int J Immunogenet 2006; 33: 127-33.
43. Munerato P, Azevedo ML, Sucupira MC, et al. Frequency of polymorphisms of genes coding for HIV-1 co-receptors CCR5 and CCR2 in a Brazilian population. Braz J Infect Dis 2003; 7:236-40.
44. Acosta AX, Sampaio RG, Spinola JL, GaIvão-Castro B. Distribution of the CCR2-64I allele in three Brazilian ethnic groups. Genet Mol Biol 2003; 26: 241-3.
45. Wang FS, Hong WG, Cao Y, et al. Population survey of CCR5 delta32, CCR5 m303, CCR2b 64I, and SDF1 3′A allele frequencies in indigenous Chinese healthy individuals, and in HIV-1-infected and HIV-1-uninfected individuals in HIV-1 risk groups. J Acquir Immune Defic Syndr 2003; 32: 124-30.
46. Passos GA Jr, Picanco VP. Frequency of the delta ccr5 deletion allele in the urban Brazilian population. Immunol Lett 1998; 61: 205-7.
47. Grimaldi P, Shindo N, Acosta AX, et al. Prevalence of the CCR5Delta32 mutation in Brazilian populations and cell susceptibility to HIV-1 infection. Hum Genet 2002; 111: 102-4.
48. Bratt G, Leandersson AC, Albert J, Sandstrom E, Wahren B. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals. AIDS 1998; 12: 729-36.
49. Katzenstein TL, Eugen-Olsen J, Hofmann B, et al. HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 10-4.
50. Laurichesse JJ, Persoz A, Theodorou I, et al. Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion. HIV Med 2007; 8: 213-9.
51. Rizzardi GP, Morawetz RA, Vicenzi E, et al. CCR2 polymorphism and HIV disease. Swiss HIV Cohort. Nat Med 1998; 4: 252-3.
52. Mulherin SA, O'Brien TR, Ioannidis JP, et al. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS 2003; 17: 377-87.
53. Nakayama EE, Tanaka Y, Nagai Y, et al. A CCR2-V64I polymorphism affects stability of CCR2A isoform. AIDS 2004; 18: 729-38.
54. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1. Nature 1998; 391: 240.
55. Soriano A, Martinez C, Garcia F, et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDFI-3′A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis 2002; 186: 922-31.
56. Ruibal-Ares BH, Belmonte L, Bare PC, Parodi CM, Massud I, de Bracco MM. HIV-1 infection and chemokine receptor modulation. Curr HIV Res 2004; 2: 19-50.
57. Xiang J, George SL, Wunschmann S, Chang Q, Klinzman D, Stapleton JT. Inhibition of Hiv-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 2004; 363: 2040-6.
58. Brumme ZL, Chan KJ, Dong W, et al. CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response. AIDS 2001; 15: 2259-66.
59. Silverberg MJ, Wegner SA, Milazzo MJ, et al. Effectiveness of highly-active antiretroviral therapy by race/ethnicity. AIDS 2006; 20: 1531-8.